C WorldWide Group Holding A S cut its holdings in Celgene Co. (NASDAQ:CELG) by 22.6% during the first quarter, Holdings Channel reports. The firm owned 97,986 shares of the biopharmaceutical company’s stock after selling 28,564 shares during the quarter. C WorldWide Group Holding A S’s holdings in Celgene were worth $9,244,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of CELG. Oregon Public Employees Retirement Fund raised its holdings in shares of Celgene by 9,691.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 16,495,997 shares of the biopharmaceutical company’s stock valued at $257,000 after purchasing an additional 16,327,522 shares during the last quarter. Norges Bank acquired a new stake in shares of Celgene in the fourth quarter valued at approximately $484,390,000. Parnassus Investments CA raised its holdings in shares of Celgene by 1,766.7% in the fourth quarter. Parnassus Investments CA now owns 2,800,000 shares of the biopharmaceutical company’s stock valued at $179,452,000 after purchasing an additional 2,650,000 shares during the last quarter. Boussard & Gavaudan Investment Management LLP acquired a new stake in shares of Celgene in the first quarter valued at approximately $186,113,000. Finally, BlackRock Inc. raised its holdings in shares of Celgene by 2.8% in the fourth quarter. BlackRock Inc. now owns 53,650,909 shares of the biopharmaceutical company’s stock valued at $3,438,486,000 after purchasing an additional 1,459,100 shares during the last quarter. Institutional investors own 71.71% of the company’s stock.
Shares of CELG opened at $95.51 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.66 and a current ratio of 2.78. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $97.07. The firm has a market cap of $66.97 billion, a P/E ratio of 11.35, a PEG ratio of 0.43 and a beta of 1.68.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the Zacks’ consensus estimate of $2.45 by $0.10. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The firm had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.01 billion. During the same period in the previous year, the business posted $2.05 earnings per share. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. On average, analysts predict that Celgene Co. will post 9.85 earnings per share for the current year.
A number of analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. ValuEngine upgraded shares of Celgene from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. Mizuho restated a “buy” rating and set a $103.00 target price on shares of Celgene in a report on Thursday. Barclays downgraded shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price on the stock. in a report on Friday, May 3rd. Finally, BidaskClub downgraded shares of Celgene from a “hold” rating to a “sell” rating in a report on Thursday, April 25th. Twenty research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $95.96.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.